For Pharma
Not the drug. Every failed trial died the same death: the right patient, found too late. DeepSensi™ matches at the exact moment of diagnosis, simulates the cohort before a site opens, and prices the therapy in number-needed-to-treat before the first dose. One day of trial delay costs more than the pilot.
What changes
Reach the right patient when the diagnosis is made, not months after enrolment closes.
Synthetic population twins project efficacy, complications, and number-needed-to-treat before a single site opens.
Hypotheses anchored in deterministic biological-network validation, not language-model guesses.
A distributed architecture with global reach.
Live ingestion from 46 scientific databases keeps your compound’s evidence base current inside every deliberation.
Hospitals exchange validated diagnostic patterns, not records: privacy-preserving signals across borders and jurisdictions.